Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Galderma Group AG (GALD.SW)
Zug, ZG, CH
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.71% | +3.96% | +1.68% | +14.15% | +4.09% | +4.03% | +54.64% | +214.25% | +214.25% | +214.25% | +214.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 11 | 0 |
| Hold | 3 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | -1 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+18.0% ★ Q4'25: +179.6% (vs Q2'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+179.4% ★ Q4'25: +1,915.8% (vs Q2'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+19.8% ★ Q4'25: +19.0% (vs Q2'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.9% ★ Q4'25: +13.9% (vs Q2'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.4% ★ Q4'25: +15.3% (vs Q2'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.3% ★ Q4'25: -0.3% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.25× Q4'25: 1.25× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 12 EPS Ana. |
Dec 2027 17 Rev. Ana. 13 EPS Ana. |
Dec 2028 14 Rev. Ana. 8 EPS Ana. |
Dec 2029 9 Rev. Ana. 6 EPS Ana. |
Dec 2030 13 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
3.67B
est: 4.32B (-15.0%)
|
4.44B
est: 4.02B (+10.6%)
|
5.24B
est: 4.12B (+27.2%)
|
4.95B
4.93B – 5.05B
+20.1% YoY
|
5.80B
5.73B – 6.03B
+17.2% YoY
|
6.66B
6.61B – 6.87B
+14.9% YoY
|
7.48B
7.42B – 7.71B
+12.2% YoY
|
8.28B
8.22B – 8.54B
+10.8% YoY
|
| EBITDA |
690.44M
est: 824.63M (-16.3%)
|
959.00M
est: 766.91M (+25.0%)
|
1.22B
est: 787.19M (+55.4%)
|
945.15M
941.11M – 964.88M
+20.1% YoY
|
1.11B
1.10B – 1.15B
+17.2% YoY
|
1.27B
1.26B – 1.31B
+14.9% YoY
|
1.43B
1.42B – 1.47B
+12.2% YoY
|
1.58B
1.57B – 1.63B
+10.8% YoY
|
| EBIT |
511.21M
est: 542.88M (-5.8%)
|
666.00M
est: 504.88M (+31.9%)
|
885.20M
est: 518.23M (+70.8%)
|
622.22M
619.56M – 635.21M
+20.1% YoY
|
728.99M
721.01M – 757.93M
+17.2% YoY
|
837.72M
831.12M – 863.73M
+14.9% YoY
|
940.19M
932.78M – 969.38M
+12.2% YoY
|
1.04B
1.03B – 1.07B
+10.8% YoY
|
| Net Income |
-48.11M
est: -600.0K (-7,917.6%)
|
231.00M
est: 389.69M (-40.7%)
|
642.16M
est: 590.84M (+8.7%)
|
896.19M
855.10M – 1.14B
+51.7% YoY
|
1.20B
1.17B – 1.24B
+34.4% YoY
|
1.71B
1.12B – 1.75B
+42.2% YoY
|
1.89B
1.88B – 1.97B
+10.6% YoY
|
2.22B
2.20B – 2.31B
+17.1% YoY
|
| SGA |
1.89B
est: 2.21B (-14.3%)
|
2.05B
est: 2.05B (-0.1%)
|
2.99B
est: 2.11B (+41.9%)
|
2.53B
2.52B – 2.58B
+20.1% YoY
|
2.97B
2.93B – 3.08B
+17.2% YoY
|
3.41B
3.38B – 3.51B
+14.9% YoY
|
3.82B
3.79B – 3.94B
+12.2% YoY
|
4.24B
4.20B – 4.37B
+10.8% YoY
|
| EPS |
-0.22
est: 0.00 (-8,714.1%)
|
0.97
est: 1.62 (-40.2%)
|
2.72
est: 2.46 (+10.7%)
|
3.64
3.61 – 4.80
+48.2% YoY
|
5.02
4.95 – 5.22
+38.0% YoY
|
6.43
4.71 – 7.41
+27.9% YoY
|
8.00
7.92 – 8.32
+24.5% YoY
|
9.37
9.27 – 9.75
+17.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Flemming Ornskov | Chief Executive Officer & Director | 6M | — |
| Christian Marcoux | Chief Communications Officer | — | male |
| Desislava Lazarova | Global Head of Customer Education & Training | — | female |
| Emil Ivanov | Head of Strategy, Investor Relations & ESG | — | male |
| Luigi Felice La Corte | Chief Financial Officer | — | male |
| Nakisa Serry | General Counsel, Chief Compliance Officer & Interim CHRO | — | female |
| Adrian Murphy | Head of Global Operations | — | male |
| Thomas J. W. Dittrich | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GALD.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
